Compare ASRT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | LUNG |
|---|---|---|
| Founded | 1995 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 63.6M |
| IPO Year | 1997 | 2020 |
| Metric | ASRT | LUNG |
|---|---|---|
| Price | $0.77 | $2.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $6.81 |
| AVG Volume (30 Days) | 755.4K | ★ 1.1M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $137,354,000.00 | $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 9.22 | ★ 15.59 |
| 52 Week Low | $0.51 | $1.31 |
| 52 Week High | $1.04 | $9.37 |
| Indicator | ASRT | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 59.51 |
| Support Level | $0.65 | $1.57 |
| Resistance Level | $0.79 | $1.74 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 84.21 | 81.40 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.